References
- Bodemar G, Walan A. Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1978; 1: 403–407
- Ippoliti A, Elashoff J, Valenzuela J, Frankel H, Samloff I M, Korets R. Recurrent ulcer after successful treatment with cimetidine or antacid. Gastroenterology 1983; 85: 875–880
- Brook C W, Yeomans N D, McCarthy P G, Dudley F G, Smallwood R A. Relapse of duodenal ulceration after healing with omeprazole. Med J Aust 1987; 147: 595–597
- Hallerback B, Solhaug J H, Carling L, et al. Recurrent ulcer after treatment with cimetidine or sucralfate. Scand J Gastroenterol 1987; 22: 791–797
- Bianchi Porro G, Petrillo M. The natural history of peptic ulcer disease: the influence of H2-antagonist treatment. Scand J Gastroenterol 1986; 21(suppl 121)46–52
- Gough K R, Korman M G, Bardhan K D, et al. Ranitidine and cimetidine in prevention of duodenal ulcer relapse–a double blind, randomized multi-center, comparative trial. Lancet 1984; 2: 659–662
- Silvis S E. Final report on the United States multi-center trial comparing ranitidine to cimetidine as maintenance therapy following healing of duodenal ulcer. J Clin Gastroenterol 1985; 7: 482–487
- Cerulli M A, Cloud M L, Offen W W, Chernish S M, Matsumoto C. Nizatidine as maintenance therapy of duodenal ulcer disease in remission. Scand J Gastroenterol 1987; 22(suppl 136)79–83
- Bardhan K D, Cole D S, Hawkins B W, Franks C R. Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate?. Br Med J 1982; 284: 621–623
- Samloff I M, Secrist D M, Passaro E, Jr. Serum group I pepsinogen levels and their relation to gastric acid secretion in patients with and without recurrent ulcer. Gastroenterology 1976; 70: 309–313
- Stabile B E, Passaro E, Jr, Samloff I M, Walsh J H. Serum pepsinogen I and gastric acid output in postoperative recurrent peptic ulcer. Arch Surg 1978; 113: 1136–1141
- Uemura N. Serum concentration of group I pepsinogen and its clinical significance (in Japanese). Med J Hiroshima Univ 1987; 35: 587–608
- Sumii K, Uemura N, Inbe A, et al. Familial aggregation of duodenal ulcer and an autosomal dominant inheritance of hyperpepsinogenemia I. Hiroshima J Med Sci 1986; 35: 171–175
- Spiro H M, Ryan A E, Jones C M. The utility of the blood pepsin assay in clinical medicine. N Engl J Med 1955; 253: 261–266
- Anscombe A E. Plasma pepsinogen: normal and abnormal secretion. Ann R Coll Surg Engl 1964; 35: 34–49
- Battaglia G, Farini R, Di Mario F, et al. Recurrence of duodenal ulcer under continuous antisecretory treatment: an approach to the detection of predictive markers. Am J Gastroenterol 1984; 79: 831–834
- Samloff I M. Cellular localization of group I pepsinogens in human gastric mucosa by radioimmuno-fluorescence. Gastroenterology 1971; 61: 185–188
- Samloff I M, Secrist D M, Passaro E, Jr. A study of the relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology 1975; 69: 1196–1200
- Rotter J I, Petersen G, Samloff I M, et al. Genetic heterogeneity of hyperpepsinogenemic I and nor-mopepsinogenemic I duodenal ulcer disease. Ann Intern Med 1979; 91: 372–377
- Walker P, Luther J, Samloff I M, Feldman M. Life events stress and psychosocial factors in men with peptic ulcer disease. II. Relationships with serum pepsinogen concentrations and behavioral risk factors. Gastroenterology 1988; 94: 323–330
- Malesci A, Basilico M, Bersani M, Bonato C, Bal-Larin E, Ronchi G. Serum pepsinogen I elevation in cigarette smokers. Scand J Gastroenterol 1988; 23: 602–606
- Magni G, Rizzardo R, Di Mario F, Farini R, Aggio L, Naccarato R. Personality and psychological factors in chronic duodenal ulcer. Their interaction with biological parameters. Arch Sui Neurol Neur-ochir Psychi 1984; 135: 315–320
- Colgan S M, Faraghar E B, Whorwell P J. Controlled trial on hypnotherapy in relapse prevention of duodenal ulceration. Lancet 1988; 2: 1299–1300
- Korman M G, Hansky J, Eaves E R, Schmidt G T. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871–874
- Freston J W. H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patients selection. Am J Gastroenterol 1987; 82: 1242–1249
- Jensen D M. Economic and health aspects of peptic ulcer disease and H2 receptor antagonists. Am J Med 1986, suppl 4B: 42–48
- Sonnenberg A. A comparison of different strategies for treatment of duodenal ulcer. Br Med J 1985; 290: 1185–1187